BAM
MRNS

Blueshift Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Blueshift Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,724
Closed -$180K – 1124
2020
Q4 		$180K Buy
+14,724
New +$205K 0.02% 634

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Blueshift Asset Management's MRNS Position: Q1 2021 in Review

Blueshift Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2021, closing a stake of 14,724 shares — an estimated $180K sold.

Blueshift Asset Management first reported a position in MRNS in Q4 2020 and held it in 1 quarter. The position peaked at $180K in Q4 2020. 87 funds tracked by Wall St. Rank hold MRNS as of Q1 2021.

  • Blueshift Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 14,724 Marinus Pharmaceuticals, Inc shares in Q1 2021, an estimated $180K.
  • Blueshift Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2020 and held it in 1 quarter.
  • Blueshift Asset Management's Marinus Pharmaceuticals, Inc position peaked at $180K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2021.

Based on Blueshift Asset Management's 13F filing for Q1 2021, filed 6 May 2021.